At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 121 enrolled
Drug / intervention
Influenza virus vaccine +1 morebiological
Likely dose
Influenza virus vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Immunogenicity of Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® 2003/2004
In Brief
A Phase 4 clinical trial evaluating Influenza virus vaccine for Influenza. Completed, enrolled 121 participants across 1 site.
Detailed Summary
To describe the safety during days 0 to 21 following injection of the 2003-2004 formulation of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and subjects aged ≥ 60 years. To describe the immune response at 21 days following injection of the 2003-2004 formulation of the inactivated, split-virion influenza vaccine Fluzone®, in subjects aged 18-59 years and subjects aged ≥ 60 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2003
Primary CompletionSep 2003
First PostedFeb 2009
TodayJul 2026
First PostedFeb 4, 2009
Enrollment StartJul 1, 2003
Primary CompletionSep 1, 2003
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.4 years ago
Interventions
Influenza virus vaccinebiological
0.5 mL, Intramuscular
Influenza virus vaccinebiological
0.5 mL, Intramuscular